Clinical Trial Detail

NCT ID NCT03043313
Title Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER)Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER) (MOUNTAINEER)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Academic and Community Cancer Research United
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Trastuzumab + Tucatinib

Age Groups: adult senior

Additional content available in CKB BOOST